Blood circulation enhancement

"Blood circulation enhancement" does **not** refer to a single molecule, receptor, or canonical therapeutic target. Instead, it describes the general physiological process of increasing or improving the flow of blood through the circulatory system. This can be achieved by various mechanisms at the tissue and cellular level—most notably through vasodilation mediated by smooth muscle relaxation in vessel walls. Key mediators include nitric oxide and ATP released from red blood cells and endothelial cells, which act on receptors such as P2Y purinergic receptors to induce vessel relaxation and increase perfusion[1][2][4]. Drugs that improve blood flow typically do so by targeting these pathways but do not interact with an entity called "blood circulation enhancement." Therefore, this term should not be considered a valid molecular target for drug discovery or pharmacological intervention. In summary, "Blood circulation enhancement" is an imprecise term describing an outcome rather than any specific protein/receptor/target. It cannot be mapped to structured information about canonical targets without further specification of the underlying mechanism or molecular mediator involved.

Other names

Blood flow enhancementCirculatory improvementImproved blood circulation

Vasodilation via smooth muscle relaxation[2][7]; ATP-mediated purinergic signaling[1][4]; Nitric oxide-mediated guanylate cyclase activation[1][2]; Calcium channel blockade[2]